Cashu Logo
HomeWatchlistNewsSignalsPicks
DJI
+0.43%
SPX
+0.32%
IXIC
+0.38%
FTSE
+0.26%
N225
+0.55%
AXJO
+0.06%
Cashu Logo
Log In
HomeWatchlistNewsSignalsPicks
Stocks
0.00 (0.00%)
0.000
USD
At close at --,----
Cashu Logo Alt
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

  • About Us
  • Careers
  • Blog
  • News

Help & Support

  • Help Center
  • Contact Us
  • Pro Support

Legal

  • Privacy Policy
  • Terms of Use
InstagramYouTube

© 2024 Cashu PTY LTD.

Overview

Loading chart...

Key Stats

Market Cap
140.82M
Dividend Yield
0.00%
P/E Ratio
-1.06
EPS
-0.58
Revenue
98.43M
Avg. Volume
1.66M

Recently from Cashu

publisher logo
Cashu

Nektar Therapeutics: Aro Biotherapeutics Appoints New CEO to Enhance siRNA Drug Development

4 months ago
publisher logo
Cashu

Nektar Therapeutics: Aro Biotherapeutics' Leadership Change Signals New Strategic Direction

4 months ago
publisher logo
Cashu

Nektar Therapeutics Transfers PEGylation Business to Gannet BioChem for Strategic Focus Shift

6 months ago

About

What does NKTR do?
Nektar Therapeutics, a San Francisco-based biopharmaceutical company with 137 employees, focuses on developing immunotherapy medicines for oncology and immunology, including NKTR-255 and Rezpegaldesleukin. Its pipeline targets immune response pathways to address cancer and autoimmune conditions.
Sector
💻 Health Care
IPO
CEO
Employees
Headquarters
California, USA
Website
http://www.nektar.com
Join our newsletter to keep up to date with us!
Stocks
Health Care
nktr
Nektar Therapeutics
NKTR
-1.07 (-9.47%)
10.275
USD
At close at Jun 11, 14:37 UTC
Summary
News
Signals
Benchmarks
Financials